Ethical Considerations at the Intersection Between Psychedelic-Assisted Psychotherapy and Medical Assistance in Dying

Click to increase image sizeClick to decrease image size

This article refers to:

Journeying to Ixtlan: Ethics of Psychedelic Medicine and Research for Alzheimer’s Disease and Related Dementias

Notes

1 This includes both patients whose natural death is reasonably foreseeable (e.g., those with stage IV cancer) and those whose natural death is not reasonably foreseeable (e.g., people with spinal stenosis), but not those where a mental disorder is the sole underlying condition (such patients are set to become eligible to receive MAiD starting on March 17, 2024).

Additional information

Funding

Daniel Rosenbaum receives salary support from the Nikean Foundation.